title: Somatomedin C (IGF I) plasma levels after orthotopic liver transplantation (OLT) in end-stage cirrhotic patients.
abstract: Insulin-like growth factors [IGF I and II or somatomedins (SMS)] are polypeptides chemically and biologically correlated with insulin. The main source of synthetic activity and secretion is the liver, although many other tissues have been demonstrated to synthesize SMS. In the circulation, they are not present in a free form, but are mostly bound to a specific carrier protein independently synthesized in the liver. Hepatic or extrahepatic storage organs have not been demonstrated; the half life of the SMS-binding protein complex is between 3 and 4. Synthesis of SMS is regulated by GH, insulin, thyroxine and nutrition (caloric and protein intake, and nitrogen balance). The role of corticosteroids is still a matter of debate: in patients treated with steroids SMS blood levels have been shown to be within normal limits, while biological activity has been demonstrated to be significantly reduced by SMS inhibitors, probably induced by corticosteroid therapy. The biological properties of SMS are related to their structural homology with insulin, and can be summarized as follows: A. Insulin-like activity (glucose oxidation, lipogenesis, glycogen synthesis, inhibition of lipolysis and glycogenolysis); B. Sulphation activity (incorporation of sulphate and leucine into glycosaminglycans of the cartilage); C. Stimulation of fibroblast multiplication; D. Amplification of other hormone activities (GH); E. Complementary anabolic activity with insulin. Low levels of SMS have been demonstrated in hypopituitarism (secondary) or in other diseases independent of GH reduced secretion (primary) such as malnutrition, malabsorption, acute or chronic liver failure and uraemia. Negative nitrogen balance, hypocaloric and/or low protein diets are usually correlated with low levels of SMS. Recently, Schalch et al. reported on the role of orthotopic liver transplantation (OLT) in normalizing SMS blood levels in a group of end-stage liver diseased patients. This preliminary paper deals with changes in IGF-I plasma levels (somatomedin C) in a group of patients affected by end-stage liver cirrhosis before and after OLT.
authors: Department of Anaesthesia, Ospedale Niguarda Ca'Granda, Milano, Italy.
authors: A
authors: A
authors: Corti
authors: A
authors: A
authors: De Gasperi
authors: G
authors: G
authors: Oppizzi
authors: E
authors: E
authors: Pannacciulli
authors: A
authors: A
authors: Cristalli
authors: G
authors: G
authors: Fantini
authors: E
authors: E
authors: Mazza
authors: M
authors: M
authors: Prosperi
authors: A
authors: A
authors: Rocchini
authors: D
authors: D
authors: Sabbadini
authors: C
authors: C
authors: Savi
authors: A
authors: A
authors: Scaiola
authors: S
authors: S
authors: Vai
authors: F
authors: F
authors: Romani
authors: L
authors: L
authors: DeCarlis
authors: G F
authors: GF
authors: Rondinara
mesh_terms: D001646:Bile / Q000378:metabolism; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D007335:Insulin-Like Growth Factor II / Q000378:metabolism*; D008103:Liver Cirrhosis / Q000097:blood / Q000145:classification / Q000473:pathology / Q000601:surgery*; D016031:Liver Transplantation / Q000502:physiology*; D008297:Male; D009336:Necrosis
chemical_list: D007166:Immunosuppressive Agents; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II